| Literature DB >> 34611084 |
Dae Hyeon Kim1, Kwon Joong Na1, In Kyu Park1,2, Chang Hyun Kang1,2, Young Tae Kim1,2,3, Samina Park1,2.
Abstract
BACKGROUND: In general, a 2-cm surgical margin is recommended for limited resection to obtain equivalent oncologic outcomes to lobectomy for lung cancer. This study aimed to examine the patterns of recurrence and prognostic factors for recurrence in patients with a close parenchymal resection margin.Entities:
Keywords: Lung neoplasms; Recurrence; Resection margin; Segmentectomy
Year: 2021 PMID: 34611084 PMCID: PMC8548195 DOI: 10.5090/jcs.21.045
Source DB: PubMed Journal: J Chest Surg ISSN: 2765-1606
Fig. 1Flowchart showing the process of patient selection. NSCLC, non-small cell lung cancer.
Preoperative demographics
| Characteristic | Value |
|---|---|
| Age (yr) | 63.6±9.2 |
| Sex (male) | 76 (48.7) |
| History of smoking | 64 (41.0) |
| ECOG PS ≥1 | 34 (21.8) |
| Comorbidities | |
| Hypertension | 63 (40.4) |
| Diabetes mellitus | 28 (17.9) |
| Chronic obstructive pulmonary disease | 19 (12.2) |
| History of tuberculosis | 15 (9.6) |
| Cardiovascular disease | 10 (6.4) |
| History of cerebrovascular disease | 8 (5.1) |
| Chronic kidney disease | 7 (4.5) |
| Liver disease | 8 (5.1) |
| History of previous cancer | 48 (30.8) |
Values are presented as mean±standard deviation or number (%).
ECOG PS, Eastern Cooperative Oncology Group performance score.
Perioperative clinical characteristics
| Variable | Value |
|---|---|
| Size, radiologic (cm) | 1.7±0.8 |
| Type of nodule | |
| Part-solid nodule | 109 (66.9) |
| Solid nodule | 47 (30.1) |
| C/T ratio | 0.3±0.3 |
| Surgical approaches | |
| Video-assisted thoracoscopic surgery | 149 (95.5) |
| Open surgery | 7 (4.5) |
| Reasons for segmentectomy | |
| Intentional | 107 (68.6) |
| Compromised | 46 (31.4) |
| No. of resected segments | |
| 1 | 73 (46.8) |
| 2 | 27 (17.3) |
| 3 | 46 (29.5) |
| 4 | 10 (6.4) |
| Location of tumor | |
| Right upper lobe | 20 (12.8) |
| Right lower lobe | 45 (28.8) |
| Left upper lobe | 56 (35.9) |
| Left lower lobe | 35 (22.4) |
| Postoperative complication | 17 (10.8) |
| Pneumonia | 4 (2.6) |
| Prolonged air leakage | 3 (1.9) |
| Atrial fibrillation | 5 (3.2) |
| Others | 5 (3.2) |
| Postoperative mortality | 0 |
Values are presented as mean±standard deviation or number (%).
C/T ratio, consolidation-to-tumor ratio of part-solid nodules.
Pathologic results
| Variable | Value |
|---|---|
| Stage (seventh-edition TNM) | |
| IA | 133 (85.3) |
| IB | 23 (14.7) |
| Size, pathologic (cm) | 1.6±0.8 |
| Parenchymal margin (cm) | 1.1±0.6 |
| Bronchial margin (cm) | 2.5±1.4 |
| Visceral pleural invasion | 16 (10.3) |
| Vascular invasion | 2 (1.3) |
| Lymphatic invasion | 18 (11.5) |
| Histologic type | |
| Adenocarcinoma | 145 (92.9) |
| Lepidic | 49 (33.8) |
| Acinar | 46 (31.7) |
| Papillary | 19 (13.1) |
| Micropapillary | 1 (0.7) |
| Solid | 3 (2.1) |
| Mucinous | 6 (4.1) |
| Squamous cell carcinoma | 11 (7.1) |
Values are presented as mean±standard deviation or number (%).
TNM, tumor-node-metastasis.
Patterns of recurrence (N=17)
| Variable | No. (%) |
|---|---|
| Isolated local recurrence | |
| Bronchial stump | 1 (0.6) |
| Lung, staple line | 1 (0.6) |
| Lung, residual lobe | 1 (0.6) |
| Isolated regional recurrence | |
| Mediastinal LNs | 1 (0.6) |
| Distant recurrence | |
| Lung, ipsilateral | 2 (1.3) |
| Lung, contralateral | 4 (2.6) |
| Bone | 2 (1.3) |
| Pleural seeding | 2 (1.3) |
| Brain | 0 |
| Combined recurrence | |
| Lung, residual lobe+mediastinal LNs | 1 (0.6) |
| Lung, staple line+contralateral lung | 1 (0.6) |
| Lung, ipsilateral+mediastinal LNs | 1 (0.6) |
LN, lymph node.
Fig. 2Kaplan-Meier curve for overall survival (A) and recurrence-free survival (B). Thin lines: 95% confidence limits.
Cox regression analysis for recurrence-free survival
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
|
|
| ||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age >65 yr | 4.15 (1.35–12.74) | 0.013 | 5.95 (1.48–23.86) | 0.012 | |
| Male | 9.33 (2.13–40.84) | 0.003 | |||
| Smoking history | 4.18 (1.47–11.89) | 0.007 | |||
| ECOG PS ≥1 | 2.37 (0.90–6.25) | 0.080 | 3.24 (0.99–10.56) | 0.050 | |
| Compromised surgery | 6.10 (2.14–17.33) | 0.001 | 1.59 (0.39–6.39) | 0.217 | |
| Solid nodule on computed tomography | 7.29 (2.55–20.86) | <0.001 | |||
| Mediastinal lymph node dissection | 0.58 (0.13–2.55) | 0.473 | 0.13 (0.02–0.85) | 0.034 | |
| Complication | 5.87 (2.16–15.90) | 0.000 | 10.27 (2.98–35.37) | 0.000 | |
| Size >2 cm | 9.02 (3.17–25.65) | <0.001 | 9.16 (2.89–29.04) | <0.001 | |
| Parenchymal resection margin >1 cm | 2.25 (0.79–6.40) | 0.127 | 2.82 (0.91–8.70) | 0.071 | |
| Margin/tumor ratio >1 | 0.13 (0.01–1.03) | 0.054 | 0.60 (0.06–5.9) | 0.663 | |
| Histologic type | <0.001 | 0.001 | |||
| Squamous cell carcinoma | 9.02 (3.17–25.65) | 7.45 (2.21–25.10) | |||
| Adenocarcinoma | 1 (Reference) | 1 (Reference) | |||
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score.
Cox regression analysis for overall survival
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
|
|
| ||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age >65 yr | 1.21 (0.30–4.85) | 0.784 | |||
| Male | 3.54 (0.71–17.57) | 0.122 | |||
| Smoking history | 5.01 (1.00–24.93) | 0.049 | |||
| ECOG PS ≥1 | 1.09 (0.21–5.44) | 0.914 | |||
| Compromised surgery | 3.97 (0.95–16.66) | 0.059 | 4.81 (1.11–20.86) | 0.036 | |
| Solid nodule on computed tomography | 1.43 (0.34–6.01) | 0.620 | |||
| Mediastinal lymph node dissection | 0.23 (0.04–1.18) | 0.079 | |||
| Complication | 9.43 (2.35–37.86) | 0.002 | 11.04 (2.63–46.27) | 0.001 | |
| Size >2 cm | 2.05 (0.49–8.61) | 0.323 | |||
| Parenchymal resection margin >1 cm | 0.54 (0.12–2.26) | 0.402 | |||
| Margin/tumor ratio >1 | 0.32 (0.04–2.66) | 0.297 | |||
| Histologic type | |||||
| Squamous cell carcinoma | 2.16 (0.26–17.69) | 0.471 | |||
| Adenocarcinoma | 1 (Reference) | 1 (Reference) | |||
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score.